Patents Assigned to Ceva Sante Animale
  • Method for the treatment of valvular heart disease comprising administering a composition comprising sarpogrelate
    Patent number: 11116741
    Abstract: The present invention relates to the use of a serotoninergic receptor antagonist, such as sarpogrelate or compositions thereof, for the treatment and/or prevention of heart damages in mammals.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: September 14, 2021
    Assignee: CEVA SANTE ANIMALE
    Inventors: Estelle Ayme-Dietrich, Jérôme Guyonnet, Roland Lawson, Luc Maroteaux, Laurent Monassier
  • Palatable oral veterinary compositions
    Patent number: 11090270
    Abstract: The present invention is directed to palatable veterinary compositions made from one or more pharmaceutical active ingredients having a smell and/or a taste that is repulsive to animals, and a preparation method for preparing oral veterinary compositions. Various aspects of the present invention are related to preparing palatable veterinary compositions that comprises mixing one or more pharmaceutical active ingredients having a smell with one or more palatabilizing agents.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: August 17, 2021
    Assignee: Ceva Santé Animale
    Inventors: Laurence Peyrot, Florence Guimberteau
  • Palatable oral veterinary compositions
    Patent number: 11020350
    Abstract: The present invention concerns palatable veterinary compositions made from one or more pharmaceutical active ingredients having a smell and/or a taste that is repulsive to animals, and a preparation method for preparing said oral veterinary compositions.
    Type: Grant
    Filed: June 1, 2013
    Date of Patent: June 1, 2021
    Assignee: Ceva Santé Animale
    Inventors: Laurence Peyrot, Florence Guimberteau
  • Multivalent recombinant SPV
    Patent number: 11020472
    Abstract: The present invention relates to novel recombinant swinepox viruses and their use in vaccine compositions. The recombinant swinepox viruses of the invention are doubly defective for IL18bp and TK genes, and comprise at least one foreign gene cloned into defective TK gene sequence. The invention is particularly suited to produce swine vaccines, particularly for vaccinating swine against PCV2 infection.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: June 1, 2021
    Assignee: CEVA SANTE ANIMALE
    Inventors: Takanori Sato, Shuji Saitoh, Yasutoshi Komiya
  • Methods for controlling the spread of dirofilariosis
    Patent number: 10952988
    Abstract: This invention relates to a method of controlling the spread of dirofilariosis, such as for example heartworm, by administering to at least one non-human animal infested with filarioid nematodes such as Dirofilaria spp or susceptible to have been infested with filarioid nematodes such as Dirofilaria spp, an effective dose of a combination of a neonicotinoid compound and a pyrethroid compound.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: March 23, 2021
    Assignee: Ceva Santé Animale
    Inventors: Marie Varloud, Elizabeth Hodgkins
  • VACCINE COMPOSITION AGAINST STREPTOCOCCUS SUIS INFECTION
    Publication number: 20210015910
    Abstract: Described is a vaccine composition comprising an effective amount of at least one polypeptide selected from the group of IdeSsuis, rldeSsuis, an analogue or a fragment thereof, or a polynucleotide encoding the same. This vaccine composition is used in the prophylactic, metaphylactic or therapeutic treatment of a Streptococcus suis infections in pigs or humans.
    Type: Application
    Filed: August 5, 2020
    Publication date: January 21, 2021
    Applicant: Ceva Santé Animale S.A.
    Inventors: Jana Seele, Christoph Baums, Peter Valentin-Weigand
  • Duck Enteritis Virus and the uses thereof
    Patent number: 10821170
    Abstract: The present invention relates to DEV and the uses thereof. The invention is particularly suited to vaccinate poultry against avian pathogens.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: November 3, 2020
    Assignee: CEVA SANTE ANIMALE
    Inventors: Saeki Yukari, Shuji Saitoh
  • Duck enteritis virus and the uses thereof
    Patent number: 10717967
    Abstract: The present invention relates to DEV and the uses thereof. The invention is particularly suited to vaccinate poultry against avian pathogens.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: July 21, 2020
    Assignee: CEVA SANTE ANIMALE
    Inventors: Saeki Yukari, Shuji Saitoh
  • Duck Enteritis Virus and the uses thereof
    Patent number: 10711254
    Abstract: The present invention relates to DEV and the uses thereof. The invention is particularly suited to vaccinate poultry against avian pathogens.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: July 14, 2020
    Assignee: CEVA SANTE ANIMALE
    Inventors: Saeki Yukari, Shuji Saitoh
  • Duck enteritis virus and the uses thereof
    Patent number: 10711255
    Abstract: The present invention relates to DEV and the uses thereof. The invention is particularly suited to vaccinate poultry against avian pathogens.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: July 14, 2020
    Assignee: CEVA SANTE ANIMALE
    Inventors: Saeki Yukari, Shuji Saitoh
  • Duck enteritis virus and the uses thereof
    Patent number: 10704028
    Abstract: The present invention relates to DEV and the uses thereof. The invention is particularly suited to vaccinate poultry against avian pathogens.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: July 7, 2020
    Assignee: CEVA SANTE ANIMALE
    Inventors: Saeki Yukari, Shuji Saitoh
  • COMPOSITIONS AND USES THEREOF FOR CONTROLLING ECTOPARASITES IN NON-HUMAN MAMMALS
    Publication number: 20200163339
    Abstract: The invention relates to novel veterinary compositions comprising an effective amount of a neonicotinoid compound and an effective amount of a N-arylpyrazole compound. The invention also relates to the use of such compositions for controlling ectoparasites in a non-human mammal.
    Type: Application
    Filed: January 29, 2020
    Publication date: May 28, 2020
    Applicant: Ceva Santé Animale
    Inventors: Hamadi Karembe, Marie Varloud
  • PALATABLE ORAL VETERINARY COMPOSITIONS
    Publication number: 20200163891
    Abstract: The present invention concerns palatable veterinary compositions made from one or more pharmaceutical active ingredients having a smell and/or a taste that is repulsive to animals, and a preparation method for preparing said oral veterinary compositions.
    Type: Application
    Filed: January 29, 2020
    Publication date: May 28, 2020
    Applicant: Ceva Santé Animale
    Inventors: Laurence Peyrot, Florence Guimberteau
  • Multivalent recombinant avian herpes viruses and vaccines for immunizing avian species
    Patent number: 10500270
    Abstract: The present invention relates to a recombinant avian herpes virus, which comprises at least two recombinant nucleotide sequences, each recombinant nucleotide sequence encoding a distinct antigenic peptide, wherein the at least two recombinant nucleotide sequences are inserted into distinct non-coding regions of the viral genome chosen among the region located between UL44 and UL45, the region located between UL45 and UL46, the region located between US10 and SORF3, and the region located between SORF3 and US2.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: December 10, 2019
    Assignee: CEVA SANTE ANIMALE
    Inventors: Ayumi Fujisawa, Mayumi Kubomura, Sakiko Saeki, Shuji Saito
  • Recombinant MDV1 and the uses thereof
    Patent number: 10246685
    Abstract: The present invention relates to recombinant MDV1 viruses and the uses thereof. The invention is particularly suited to vaccinate poultry against avian pathogens.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: April 2, 2019
    Assignee: CEVA SANTE ANIMALE
    Inventors: Yukari Ishihara, Motoyuki Esaki, Shuji Saitoh
  • Multivalent recombinant avian herpes viruses and vaccines for immunizing avian species
    Patent number: 10245315
    Abstract: The present invention relates to a recombinant avian herpes virus, which comprises at least two recombinant nucleotide sequences, each recombinant nucleotide sequence encoding a distinct antigenic peptide, wherein the at least two recombinant nucleotide sequences are inserted into distinct non-coding regions of the viral genome chosen among the region located between UL44 and UL45, the region located between UL45 and UL46, the region located between US10 and SORF3, and the region located between SORF3 and US2.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: April 2, 2019
    Assignee: CEVA SANTE ANIMALE
    Inventors: Ayumi Fujisawa, Mayumi Kubomura, Sakiko Saeki, Shuji Saito
  • Duck enteritis virus and the uses thereof
    Patent number: 10202582
    Abstract: The present invention relates to DEV and the uses thereof. The invention is particularly suited to vaccinate poultry against avian pathogens.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: February 12, 2019
    Assignee: CEVA SANTE ANIMALE
    Inventors: Saeki Yukari, Shuji Saitoh
  • Recombinant Marek's disease viruses and uses thereof
    Patent number: 10188720
    Abstract: The present invention relates recombinant viruses and the uses thereof. More particularly, the invention relates to novel recombinant Marek's disease viruses encoding polypeptide(s) of interest, and their use to express or deliver such polypeptides to animals, particularly poultry. The invention is particularly suited to vaccinate poultry against avian pathogens.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: January 29, 2019
    Assignee: CEVA SANTE ANIMALE
    Inventors: Motoyuki Esaki, Shuji Saitoh, Takanori Sato
  • Fusion polypeptides and vaccines
    Patent number: 10174084
    Abstract: The present invention relates to novel immunogenic polypeptides and their use in vaccine compositions. The invention also relates to nucleic acids, vectors and cells which express the polypeptides and the uses thereof. The polypeptides of the invention more specifically comprise an immunogenic domain and a cell membrane addressing domain which is derived from a B5R gene. The invention is particularly suited to produce vaccines for non-human animals, particularly for vaccinating swine against PCV2 infection.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: January 8, 2019
    Assignee: CEVA SANTE ANIMALE
    Inventor: Takanori Sato
  • Jug
    Patent number: D883104
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: May 5, 2020
    Assignee: CEVA SANTÉ ANIMALE
    Inventor: Jean-François Castaing